Registry of patients with low grade gliomas
Official title: Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas: The LOG-Glio-Project
Run by University of Ulm · NCT02686229 · Data updated 2026-11-12
This study is collecting information from patients with low grade gliomas to see how the disease behaves and what factors might affect treatment and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | University of Ulm Academic / other |
| Locations | 1 site (Ulm) |
| Status | Recruiting |
| Started | November 15, 2015 |
| Main results expected | December 31, 2026 |
| Study ends | December 2036 |
| Registry record updated | May 11, 2023 |
| Trial ID | NCT02686229 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with a radiologically suspected diagnosis of low grade glioma.
✕Probably not a fit
Patients with severe neurological or psychiatric disorders that prevent informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The LoG-Glio-Registry collects comprehensive data on patients diagnosed with low grade gliomas from a network of German hospitals. This observational study focuses on gathering radiological, clinical, epidemiological, and molecular information to better understand the disease profile and clinical outcomes. By analyzing this data, researchers aim to identify patterns and factors that influence the progression and treatment of low grade gliomas.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of low grade gliomas, leading to improved patient management and treatment strategies.
How similar studies have gone: Other studies utilizing registry approaches for gliomas have shown promise in understanding disease characteristics and outcomes, indicating that this methodology is supported by previous successes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with radiological suspected diagnosis of a low grade glioma * Age ≥ 18 years. There is no upper age limit. Exclusion Criteria: * Severe neurological or psychiatric disorder interfering with ability to give an informed consent * No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation * No consent for bio-banking of patient's biological specimens and performance of analyses on stored material.
Where it's running
-
University of Ulm
Ulm, Germany Recruiting
Study contacts
- Study coordinator: Jan Coburge, MD
- Email: jan.coburger@uni-ulm.de
- Phone: 082219628858
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.